Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 351-356

  Fang, Shencun ^a   Zhu, Wei ^b   Zhang, Yingming ^a   Shu, Yongqian ^b   Liu, Ping ^b  

^a NANJING CHEST HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

BCL 2; BCL XL; MDR1; Multidrug resistance; NF B; Paeoniflorin

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PAEONIFLORIN; PROTEIN BCL 2; PROTEIN BCL XL; RHODAMINE 123; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG INHIBITION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MODULATION; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-X PROTEIN; BENZOIC ACIDS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GLUCOSIDES; HUMANS; NF-KAPPA B; P-GLYCOPROTEIN; PAEONIA; PLANT ROOTS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS;

PAEONIA LACTIFLORA;

EID: 84862942390     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.652     Document Type: Article

References (37)

1. Fan D, Zhang X, Chen X, Mou Z, Hu J, Zhou S, Ding J and Wu K: Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 20: 360-365, 2005. (Pubitemid 40469334)
2. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007. (Pubitemid 46137553)
3. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002. (Pubitemid 34161136)
4. Zhang K, Mack P and Wong KP: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 12: 871-882, 1998. (Pubitemid 28133581)
5. Szakacs G, Paterson JK, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006. (Pubitemid 43336035)
6. Choi BH, Kim CG, Lim Y, Shin SY and Lee YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 259: 111-118, 2008. (Pubitemid 350235095)
7. Baud V and Karin M: Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40, 2009.
8. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V: NFkappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97, 2003. (Pubitemid 36152887)
9. Chen C, Edelstein LC and Gélinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687-2695, 2000. (Pubitemid 30183487)
10. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
11. Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18: 6910-6924, 1999.
12. Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342-7351, 2001. (Pubitemid 33078205)
13. Kim ID and Ha BJ: Paeoniflorin protects RAW 264.7 macrophages from LPS-induced cytotoxicity and genotoxicity. Toxicol In Vitro 23: 1014-1019, 2009.
14. Lee B, Shin YW, Bae EA, Han SJ, Kim JS, Kang SS and Kim DH: Antiallergic effect of the root of Paeonia lactiflora and its constituents paeoniflorin and paeonol. Arch Pharm Res 31: 445-450, 2008.
15. Liu DF, Wei W and Song LH: Protective effect of paeoniflorin on immunological liver injury induced by bacillus Calmette-Guerin plus lipopolysaccharide: modulation of tumour necrosis factor-alpha and interleukin-6 MRNA. Clin Exp Pharmacol Physiol 33: 332-339, 2006.
16. Zhong SZ, Ge QH and Li Q: Peoniflorin attentuates Abeta((1-42))-mediated neurotoxicity by regulating calcium homeostasis and ameliorating oxidative stress in hippocampus of rats. J Neurol Sci 280: 71-78, 2009.
17. Hung JY, Yang CJ, Tsai YM, Huang HW and Huang MS: Antiproliferative activity of paeoniflorin is through cell cycle arrest and the Fas/Fas ligand-mediated apoptotic pathway in human non-small cell lung cancer A549 cells. Clin Exp Pharmacol Physiol 35: 141-147, 2008.
18. Wu H, Li W, Wang T, Shu Y and Liu P: Paeoniflorin suppresses NF-kappaB activation through modulation of I-kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells. Biomed Pharmacother 62: 659-666, 2008.
19. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J and Fan D: miR-15b and miR-16 modulate multidrug resistance by targeting BCL-2 in human gastric cancer cells. Int J Cancer 123: 372-379, 2008. (Pubitemid 351842022)
20. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M and Iwakura S: Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br J Cancer 66: 794-799, 1992.
21. Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, Iwahashi M and Uchiyama K: Locoregional chemotherapy for patients with pancreatic cancer intraarterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 25: 366-372, 2002. (Pubitemid 35247215)
22. Xia W, Zhao T, Lv J, Xu S, Shi J, Wang S, Han X and Sun Y: Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J Cell Biochem 108: 181-194, 2009.
23. Greten FR and Karin M: The IKK/NF-kappaB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 206: 193-199, 2004. (Pubitemid 38317289)
24. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M and Katano M: Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7: 4136-4142, 2001. (Pubitemid 34044638)
25. Brown M, Cohen J, Arun P, Chen Z and Van Waes C: NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 12: 1109-1122, 2008.
26. Li J, Jia H, Xie L, Wang X, Wang X, He H, Lin Y and Hu L: Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer 19: 1421-1426, 2009.
27. Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, Saetta AA, Tsigris C, Rallis G, Vlasis K and Patsouris E: Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaδα and prognostic significance. Virchows Arch 450: 519-527, 2007. (Pubitemid 46676248)
28. Guo X, Ma N, Wang J, Bu X, Cheng Y, Sun K, Xiong H, Jiang G, Zhang B, Wu M and Wei L: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375-383, 2008.
29. Zhang H, Wu JS and Peng F: Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells. Anticancer Drugs 19: 125-132, 2008.
30. Zhang Y, Shi Y, Li X, Du R, Luo G, Xia L, Du W, Chen B, Zhai H, Wu K and Fan D: Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol Ther 7: 540-546, 2008. (Pubitemid 351847029)
31. Morais C, Gobe G, Johnson DW and Healy H: Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis 15: 412-425, 2010.
32. Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H, Noshiro H, Tanaka M, Morisaki T and Katano M: Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells. Clin Cancer Res 9: 5409-5416, 2003. (Pubitemid 37413597)
33. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
34. Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW and Hong JT: Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 32: 755-765, 2009.
35. Flaherty KT, Stevenson JP and O'Dwyer PJ: Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol 13: 499-505, 2001. (Pubitemid 33027903)
36. Klasa RJ, Gillum AM, Klem RE and Frankel SR: Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12: 193-213, 2002. (Pubitemid 34815931)
37. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S and Bold RJ: Targeting BCL-2 overexpression in various human malignancies Through NF-κB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56: 46-54, 2005. (Pubitemid 41201755)